Oryzon Genomics - KOL event: Offering a real-world solution in BPD
Oryzon hosted a key opinion leader (KOL) event highlighting the potential of vafidemstat in borderline personality disorder (BPD). The KOLs...
231 Views
Oryzon Genomics - PORTICO update with planned FDA EoP2
Oryzon Genomics has announced top-line results for the Phase IIb trial (PORTICO) assessing vafidemstat in borderline personality disorder (BPD),...
304 Views
Oryzon Genomics - Grant to bolster ALS pipeline, add funding
Oryzon has announced the receipt of a $0.5m grant from the Amyotrophic Lateral Sclerosis (ALS) Association to support the regulatory clinical...
304 Views
Oryzon Genomics - Key €45m funding to back strategic priorities
Oryzon has secured funding of up to €45m through a revised convertible bond financing agreement with Nice & Green, a Switzerland-based...
355 Views
Oryzon Genomics - Q323 recap ahead of key clinical stages
Oryzon’s Q323 results recapped the clinical progression across its drug development pipeline. The company continues to develop therapies that...
363 Views